Cerus Corp

Cerus Corporation is a blood safety company dedicated to safeguarding the world's blood supply. The company develops and supplies pathogen reduction technologies and pathogen-protected blood components to blood centers, hospitals, and patients. Its core product, the INTERCEPT Blood System for platelets and plasma, is the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for producing Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex or IFC), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The company's INTERCEPT red blood cell system is under regulatory review in Europe and in late-stage clinical development in the U.S. Cerus also maintains a significant government contract partnership with BARDA to advance its red blood cell system development. The company trades on Nasdaq under the ticker CERS. Updated Jul 30, 2026